Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
07-10 June, 2026
Not Confirmed
Not Confirmed
09-11 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
07-10 June, 2026
Industry Trade Show
Not Confirmed
09-11 June, 2026
Digital content

21 May 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260515085966/en/A2-Biotherapeutics-Presents-Safety-and-Efficacy-Data-from-the-EVEREST-2-Clinical-Study-Including-Update-on-the-First-Complete-Response-to-CAR-T-Cell-Therapy-in-a-Patient-with-Non-Small-Cell-Lung-Cancer

22 Apr 2026
// PRESS RELEASE
https://www.a2bio.com/a2-biotherapeutics-to-highlight-progress-of-car-t-cell-clinical-programs-in-three-poster-presentations-during-the-american-society-of-clinical-oncology-asco-2026-annual-meeting/

01 Apr 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260331789509/en/A2-Biotherapeutics-Receives-U.S.-FDA-Fast-Track-Designation-for-A2B543-a-Logic-Gated-CAR-T-Cell-Therapy-Enhanced-with-a-Membrane-Tethered-IL-12-Booster

26 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260225216939/en/A2-Biotherapeutics-Doses-First-Patient-in-EVEREST-2-Study-with-A2B543-a-Logic-Gated-CAR-T-Cell-Therapy-Enhanced-with-a-Membrane-Tethered-IL-12-Booster

08 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260106828941/en/A2-Biotherapeutics-Announces-FDA-Clearance-of-IND-for-A2B543-for-Treatment-of-Adults-with-Recurrent-Unresectable-Locally-Advanced-or-Metastatic-Solid-Tumors-that-Express-Mesothelin-and-Have-Lost-HLA-A02-Expression

07 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251031980313/en/A2-Biotherapeutics-Presents-Initial-Safety-and-Efficacy-Data-from-Ongoing-Phase-12-EVEREST-2-Study-Including-First-Report-of-a-Complete-Response-to-CAR-T-Cell-Therapy-in-a-Patient-with-NSCLC
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE